Radiation sensitization of human cervical cancer by proteasome inhibitor Velcade (Bortezomib)

被引：0
|
作者：
Kamer, S.
Ren, Q.
Sui, Y. P.
Kari, C.
Rodeck, U.
Dicker, A. P.
机构：
[1] Thomas Jefferson Univ, Dept Radiat Oncol, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2006年 / 66卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2006.07.742
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2334
引用
收藏
页码：S396 / S396
页数：1
相关论文
共 50 条
  • [21] The Effect of Proteasome Inhibitor Velcade on Tumor Microenvironment
    Sun, X.
    He, F.
    Ackerstaff, E.
    Xing, L.
    Minami, A.
    Carlin, S.
    Ling, C.
    Koutcher, J.
    Li, G.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S171 - S171
  • [22] Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
    Boccadoro, Mario
    Morgan, Gareth
    Cavenagh, Jamie
    [J]. CANCER CELL INTERNATIONAL, 2005, 5 (1)
  • [23] Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
    Mario Boccadoro
    Gareth Morgan
    Jamie Cavenagh
    [J]. Cancer Cell International, 5
  • [24] The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis
    Brooks, AD
    Ramirez, T
    Toh, U
    Onksen, J
    Elliott, PJ
    Murphy, WJ
    Sayers, TJ
    [J]. TUMOR PROGRESSION AND THERAPEUTIC RESISTANCE, 2005, 1059 : 160 - 167
  • [25] Hypoxia increases potency of the proteasome inhibitor VELCADE™ (bortezomib) for injection:: potential for a hypoxic cell cytotoxin in solid tumors
    Neumeier, H
    Hoar, K
    Pink, M
    Pien, C
    Sadis, S
    Tsai, F
    Bolen, J
    Read, M
    Steiner, P
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 : S166 - S166
  • [26] Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells
    Codony-Servat, J
    Tapia, MA
    Bosch, M
    Oliva, C
    Domingo-Domenech, J
    Mellado, B
    Rolfe, M
    Ross, JS
    Gascon, P
    Rovira, A
    Albanell, J
    [J]. MOLECULAR CANCER THERAPEUTICS, 2006, 5 (03) : 665 - 675
  • [27] Human metabolism of the proteasome inhibitor bortezomib: Identification of circulating metabolites
    Pekol, T
    Daniels, JS
    Labutti, J
    Parsons, I
    Nix, D
    Baronas, E
    Hsieh, F
    Gan, LS
    Miwa, G
    [J]. DRUG METABOLISM AND DISPOSITION, 2005, 33 (06) : 771 - 777
  • [28] Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment
    Montagut, C
    Rovira, A
    Mellado, B
    Gascon, P
    Ross, JS
    Albanell, J
    [J]. DRUGS OF TODAY, 2005, 41 (05) : 299 - 315
  • [29] Bortezomib, a proteasome inhibitor, in cancer therapy: from concept to clinic
    Albanell, J
    Adams, J
    [J]. DRUGS OF THE FUTURE, 2002, 27 (11) : 1079 - 1092
  • [30] Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib
    Schlesser, Camille
    Meul, Thomas
    Stathopoulos, Georgios
    Meiners, Silke
    [J]. BIOMOLECULES, 2022, 12 (06)
12345